STORY SUMMARY
The FDA wants to pull its approval of a drug. It’s not so easy.
The regulator says Tavneos was approved on the basis of manipulated study data. Should patients still have access to it?
This is a brief summary of reporting from Ars Technica Science. Read the original for the full article and context.